Eric Lefkofsky is the Co-founder of the company known as Tempus, alongside Brad Keywell. This company will primarily focus on genomic sequencing and compile data from around the healthcare industry to aid doctors in their treatments for cancer patients. Eric Lefkofsky announced not too long ago that more than 70 million dollars was raised for Tempus in their latest fundraising attempts. Since 2015, Eric Lefkofsky has managed to raise over 130 million dollars for the company, putting the company’s estimated worth at more than 700 million dollars today.
The majority of the funding for Tempus came from its co-founders, Brad and Eric. When Eric began investing in Tempus and its technology, he stated in an interview that he was prepared to invest even more capital into the company to ensure its survival and that its mission was a success. Several other companies have also hopped on board though to fund the company, including 23andMe, Revolution Growth, NEA, and more.
The technology behind Tempus is relatively new in analytics, but it will enable the company to compile a vast amount of data in the medical field from cancer patients. This data will then be used by doctors to create more precise treatments for patients, rather than a generalized treatment for most patients. As of late, Tempus has grouped up with several other companies to improve on their data compilation, including Mayo Clinic and Cleveland Clinic. The highly disorganized medical data in the healthcare industry makes providing treatments for patients much more difficult, which is why Eric took it upon himself to find a solution for this problem.
Eric Lefkofsky graduated from high school back in 1987 in Southfield Michigan. With a rather typical upbringing, the amount of success Eric has achieved today is astounding. Eric graduated from the Universty of Michigan with honors in 1991, followed by completing his studies at Michigan Law in 1993.
Eric Lefkofsky’s info: chicago.blueskyinnovation.com/vault/network/lefkofsky-eric/
Recently, the former Republican presidential nominee called Mitt Romney disclosed his past health history. He indicated that he had gone through prostate surgery the previous year due to a growing tumor detected in his body. The announcement was a sign that he would probably run for a Senate post that was currently being held by Orin Hatch in Utah.
The surgery was done successfully by a seasoned expert called Dr. Thomas Ahlering of UC Irvine Hospital in California. The prognosis was said to be in stable condition as he joined 161, 360 other men diagnosed with the illness during 2017. The American Cancer fraternity estimated a slight increase of new cases of prostate cancer for 2018.
Prostate cancer is likely to affect older men as a recent study indicated that close to 6 cases out of 10 get detected in men aged above 65 years and rare in those below the age of 40. On average, most men get diagnosed with prostate cancer at the age of 66, and Romney celebrated his 70th birthday in March 2017 thus making him susceptible to prostate cancer.
Mitt Romney joins the list of other United States politicians who have been diagnosed with prostate cancer and successfully received treatment. One of them is Colin Powel, the former Secretary of State who underwent surgery at the Walter Reed Army Medical Center to get rid of his prostate gland. Another case was identified with John Kerry in 2002 when he was running for the President of United States position. Kerry received treatment has experienced no recurrence since then.
The patients who suffer from this illness must always make informed decisions on the type of treatment they should seek. There exist two prostate cancer treatment procedures such as radiation method and surgery treatment which comes hand in hand with different sets of pros and cons. Dr. David Samad is a seasoned Urologist and has always taken time to discuss with patients on what they would face as soon as they decide on a particular procedure.
Dr. David Samadi was born and raised in Iran before living the country with his younger brother in 1978 after the Iranian Revolution broke out. They would move to the United States after having stayed in Belgium for a while. Dr. David Samadi acquired a degree in biochemistry after which he underwent postgraduate graduate training from Montefiore Medical Center.
The highest paid doctor in New York City as of 2012, Dr. David Samadi became the Chief of Robotics and Minimally Invasive Surgery.
To know more visit @: www.sharecare.com/doctor/dr-david-samadi-3
Cancer is one of the most feared diseases around the entire world. Millions of people die each year after having lost their battle to the disease. For as long as people have been able to record history, cancer has been a leading cause of death. The most common type of cancer for women is breast cancer. Prostate cancer is the most common type of cancer for men. Skin cancer is also a national health problem for both men and women.
The good news is that cancer researchers are working hard to create and evaluate methods for treating cancer. Genetic testing is the key to moving forward. New opportunities for research and application are opening up around the world, and the efforts will benefit everyone. Clay Siegall is the co-founder of Seattle Genetics, and his company is on the cutting-edge of research efforts. The following helps explain the company’s standing.
Siegall’s company leads the way in the field of oncology biotechnology. Seattle Genetics develops, tests, and markets innovated cancer drugs that base their effective action on anti-body based therapies. These drugs are clearly designed to help improve the survival rates of patients undergoing cancer treatment. Antibody-based therapy drugs are an essential component in providing both potency and stability in the fight against cancer.
Seattle Genetics remains a leader in the field by its research and break-through science. Treatments target cancers that attack a patient’s white blood cells. An example is Hodgkin’s lymphoma, which causes 8,000 new cases of cancer each year. The disease is also rampant among young people, and more than 70,000 elderly people die each year from the disease. This is an alarming number of people taken by cancer.
Seattle Genetics has also collaborated with Takeda Pharmaceutical Company Limited to produce ADCetris. The collaboration distributes the drug to 66 countries around the world. The drug presently treats Hodgkin lymphoma relapses.